Last reviewed · How we verify
Anti-IP-10 Antibody
Anti-IP-10 Antibody works by binding to IP-10, a chemokine involved in the recruitment of immune cells to sites of inflammation.
Anti-IP-10 Antibody works by binding to IP-10, a chemokine involved in the recruitment of immune cells to sites of inflammation. Used for Psoriasis.
At a glance
| Generic name | Anti-IP-10 Antibody |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Monoclonal antibody |
| Target | IP-10 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By binding to IP-10, Anti-IP-10 Antibody reduces the recruitment of immune cells to sites of inflammation, which can help to reduce inflammation and potentially treat autoimmune diseases. This mechanism is thought to be beneficial in conditions such as psoriasis and multiple sclerosis.
Approved indications
- Psoriasis
Common side effects
- Injection site reaction
Key clinical trials
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients (PHASE1)
- Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
- Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis (PHASE1)
- A Study of MDX-1100 in Subjects With Active Ulcerative Colitis (PHASE2)
- Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease (PHASE2)
- Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis (PHASE2)
- Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PHASE2)
- Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-IP-10 Antibody CI brief — competitive landscape report
- Anti-IP-10 Antibody updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI